Two studies were conducted to investigate gastrointestinal (GI) tolerance of high carbohydrate (CHO) intakes during intense running. The first study investigated tolerance of a CHO gel delivering glucose plus fructose (GLU+FRC) at different rates. The second study investigated tolerance of high intakes of glucose (GLU) vs. GLU+FRC gel. Both studies used a randomized, 2-treatment, 2-period crossover design: Endurance-trained men and women (Study 1: 26 men, 8 women; 37 ± 11 yr; 73 ± 9 kg; 1.76 ± 0.07 m. Study 2: 34 men, 14 women; 35 ± 10 yr; 70 ± 9 kg; 1.75 ± 0.09 m) completed two 16-km outdoor-runs. In Study 1 gels were administered to provide 1.0 or 1.4 g CHO/min with ad libitum water intake every 3.2 km. In Study 2 GLU or GLU+FRC gels were given in a double-blind manner to provide 1.4 g CHO/ min. In both studies a postexercise questionnaire assessed 17 symptoms on a 10-point scale (from 0 to 9). For all treatments, GI complaints were mainly scored at the low end of the scale. In Study 1 mean scores ranged from 0.00 ± 0.00 to 1.12 ± 1.90, and in Study 2, from 0.00 ± 0.0 to 1.27 ± 1.78. GI symptoms were grouped into upper abdominal, lower abdominal, and systemic problems. There were no significant treatment differences in these categories in either study. In conclusion, despite high CHOgel intake, and regardless of the blend (GLU vs. GLU+FRC), average scores for GI symptoms were at the low end of the scale, indicating predominantly good tolerance during a 16-km run. Nevertheless, some runners (~10-20%) experienced serious problems, and individualized feeding strategies might be required.
Stafford, Sparling, Rosskopf, & DiCarlo, 1992; Tsintzas, Liu, Williams, Campbell, & Gaitanos, 1993) . It is therefore common practice for athletes to ingest CHO during prolonged exercise. More recently, research efforts have focused on determining the optimal type, form, and dose of CHO to optimize exogenous CHO oxidation rates and performance. One aspect that has received little scientific attention is the practicality and gastrointestinal (GI) tolerance of CHO intake during competition.
Recently, a study in our laboratory (Currell & Jeukendrup, 2008 ) compared the effects of two different types of CHO on cycling time-trial performance after 2 hr of steady-state exercise. An 8% improvement in performance was detected for a glucose + fructose (GLU+FRU) drink compared with an isocaloric glucose (GLU) drink at an intake rate of 1.8 g/min. This observed improvement in performance coincides with the repeated finding that ingesting GLU+FRC drinks (delivering above ~1.5 g/min) results in 20-50% higher exogenous CHO oxidation rates than an isocaloric GLU drink (Jentjens, Moseley, Waring, Harding, & Jeukendrup, 2004; Jeukendrup et al., 2006) . To achieve those high CHO oxidation rates, however, large amounts of a GLU+FRC mixture (>1 g/min) have to be ingested, and this has recently been recommended to athletes competing in endurance events >2 hr (Jeukendrup, 2008) . This contemporary advice contrasts the American College of Sports Medicine consensus statement for CHO intake during exercise, which recommends 30-60 g/hr (0.5-1 g/min), based on single-source CHO intake (ACSM, 2000) . With the ingestion of a single CHO, regardless of intake rate (>2 g/min), exogenous CHO oxidation rates peak at about 1 g/min. In contrast, we now know that ingesting high amounts of multiple CHO sources (~1.5 g/min) results in 20-50% higher muscle CHO oxidation rates (Jeukendrup, 2004) . Thus, previous recommendations might need to be revisited.
Although abundant and well-controlled field data are lacking, in reality, athletes seem to fail to follow CHO intake recommendations, because the consumption of small amounts of CHO appears to be common practice (Garcia-Roves, Terrados, Fernandez, & Patterson, 1998) . Consuming large amounts of CHO in the form of most common sports drinks would require fluid intakes higher than recommended and much higher than most athletes typically consume. As a consequence, this feeding strategy could lead to GI distress, because the use of CHO drinks (Brouns & Beckers, 1993; van Nieuwenhoven, Brouns, & Kovacs, 2005) and the unaccustomed intake of high fluid volume are both linked to GI distress (Lambert et al., 2008) .
It is common for athletes in the field to consume CHO in the form of gels, which are a convenient way to ingest larger amounts of CHO. However, at present, little is known about their efficacy or their potential to cause GI distress. A number of studies investigated the effect of gels and other forms of CHO on performance (Burke, Wood, Pyne, Telford, & Saunders, 2005; Campbell, Prince, Braun, Applegate, & Casazza, 2008; Kern, Heslin, & Rezende, 2007; Patterson & Gray, 2007; Saunders, Luden, & Herrick, 2007) , but to the best of our knowledge only two studies documented gastric tolerance of gels (Burke et al.; Patterson & Gray) . In both these studies the ingestion rate of CHO was relatively low, and it is not known whether high rates of CHO intake are tolerable in a field situation when the CHO is ingested in the form of gels.
Therefore the aim of the first study was to investigate tolerance of a CHO gel delivering CHO in the form of GLU+FRC (2:1) at two rates during a 16-km fieldbased run. The reason we chose a relatively high-intensity running protocol was that running, as well as high-intensity exercise, has been associated with a higher prevalence of GI distress (Peters et al., 1999; Peters et al., 1993) .
In a second study we investigated the GI tolerance of gels with different CHO compositions. Higher oxidation rates from a combination of GLU+FRC have been related to the fact that the two CHOs use different transporters for absorption in the gut (SGLT-1 and GLUT 5 for glucose and fructose, respectively; Burant, Takeda, Brot-Laroche, Bell, & Davidson, 1992; Crane, 1965) . The combination of CHOs might also empty faster from the stomach than GLU alone (Jeukendrup & Moseley, 2008) . It can therefore be hypothesized that faster and more complete intestinal absorption leads not only to higher exogenous CHO oxidation rates but also to less residual CHO in the gut. Residual intestinal CHO has been linked to GI discomfort (Corazza, Strocchi, Rossi, Sirola, & Gasbarrini, 1988; Ravich, Bayless, & Thomas, 1983; Rumessen & Gudmand-Hoyer, 1986) , so better GI tolerance could be expected with faster gastric emptying. Hence, the purpose of the second study was to compare tolerance of gels delivering high rates of CHO in the form of either GLU or GLU+FRC.
Methods

Participants
For both studies, club-level runners and triathletes who had been running at least twice a week were recruited. They were informed about the purpose of the study, practical details, and risks associated with the procedure before giving their written consent. All participants were healthy as assessed by a general health questionnaire. The studies were approved by the School of Sport and Exercise Sciences ethics subcommittee, University of Birmingham, UK. The participant characteristics for both studies are shown in Table 1 .
Experimental Design
Both studies had a counterbalanced crossover design. Participants were randomly allocated to an order of treatment and ran 16 km on two occasions spread over three possible consecutive weekends. Thus, each participant got a 1-to 2-week washout between trials. During Study 1, participants ingested either a moderate amount of GLU+FRC gel (1 g/min; MOD) or a high dose of the same gel (1.4 g/ min; HIGH). In Study 2, participants received a high amount (1.4 g/min) of either GLU or GLU+FRC gel in a double-blind manner.
The identical course for all runs consisted of a 3.2-km closed loop on mainly flat paved roads through a park, which had to be completed five times.
Treatments
Study 1. The gels were commercially available products (PowerBar Inc., Glendale, CA) that consisted of a mixture of GLU+FRC in the ratio of 2:1. GLU was in the form of maltodextrin. Both saccharides showed similar results in studies on exogenous CHO oxidation (Wallis, Rowlands, Shaw, Jentjens, & Jeukendrup, 2005) , but maltodextrin is less sweet than GLU and, therefore, more acceptable when paired with FRC, which is comparatively sweet. We aimed to provide CHO at an average rate of 1.0 g/min in the MOD group and at an average rate of 1.4 g/ min in the HIGH group.
Study 2. One gel consisted of GLU+FRC in the ratio of 2:1, and the other contained only GLU. GLU was again administered in the form of maltodextrin. The gels were prepared (Product Technology Center-Orbe, Nestlé Ltd., Orbe, Switzerland) and packaged so that participants and investigators were blinded to treatment. In spite of different CHO mixtures both gels had similar taste and texture. We aimed to provide CHO at an average rate of 1.4 g/min in both trials. In both studies runners had access to water (Vittel, Nestlé Waters, Cedex, France) along with the gels every 3.2 km and were allowed to drink ad libitum.
Diet and Activity Before the Runs
Participants were asked to treat the two experimental field trials as races. The day before each trial they were asked to refrain from strenuous exercise and to perform the same training in the days leading up to the runs. The runners were also asked to keep the same routine before each trial, with the same breakfast at the same time, similar to what they would do before a race. Compliance was assessed in a posttrial questionnaire. Runners were asked about their actual food intake before the race to detect high fiber or fat intakes that could lead to GI symptoms (Rehrer, van Kemenade, Meester, Brouns, & Saris, 1992) .
Race Protocol
Registration for the runs took place between 9:00 and 9:30 a.m. Before the first run of each study participants were asked to fill in a questionnaire that assessed training history, eating habits, and history of GI symptoms. After registration, runners were asked to perform their individual prerace warm-up. Body weight of the runners (in race clothes) was measured on a scale accurate to 0.1 kg (Seca 701, Seca Ltd., Birmingham, UK) during the 15 min before the start and immediately after the run. All runs commenced at approximately 10 a.m.
In the MOD trial of the first study, gels were ingested immediately before the start and after 6.4 and 9.6 km, whereas during all other trials gels were ingested before the start and after 3.2, 6.4, and 9.6 km. A CHO intake of 25 g CHO per gel pouch was assumed, and this was confirmed by weighing the pouches before and after use. Each runner had a dedicated water bottle that he or she picked up after consuming the gel and returned to the researchers after 50 m. Fluid intake was measured by weighing the bottles after each loop on a Bellini electronic scale (Mistral UK Ltd., Warrington, UK; accurate to 1 g).
GI Questionnaires
Immediately after the run, participants completed a questionnaire to assess GI symptoms. The questions about GI symptoms were similar in the prerace questionnaire, which assessed history of GI symptoms, and the postrace questionnaire, which assessed GI symptoms during the runs. The questionnaires were organized in three sections, each including four to seven questions. Section 1 addressed upper abdominal problems (reflux, heartburn, bloating, cramps, vomiting, nausea); Section 2, lower abdominal problems (intestinal cramps, flatulence, urge to defecate, left abdominal pain, right abdominal pain, loose stool, diarrhea); and Section 3, systemic problems (dizziness, headache, muscle cramp, urge to urinate). Each athlete assessed the 17 items on a 10-point scale ranging from 0, no problem at all, to 9, the worst it has ever been.
Statistical Analysis
Data for GI complaints during the runs are expressed as mean and standard deviation for each treatment. In addition, minimum and maximum scores are reported. Differences between treatments were calculated as differences between mean values for each complaint and reported together with the standard error. All other data are reported as M ± SD.
Because scores were mainly recorded in the "no problem at all" category, data are not approximately normally distributed, and a nonparametric statistical approach was chosen. In the primary measure, because overall 17 questions were answered, the false positive rate of 5% will be inflated as a result of multiplicity. To reduce multiplicity, statistical analysis was performed by section of the questionnaire (upper abdominal problems, lower abdominal problems, and systemic problems). The responses of a participant over a section of symptoms were averaged. Sections of symptoms were analyzed by Wilcoxon's signed-rank tests on averages. For secondary measures, individual questions were analyzed via Wilcoxon's signed-rank tests. The p values of the Wilcoxon's signed-rank tests were not adjusted for multiple tests. Therefore, the p values serve as a flag to indicate interesting results.
Upper and lower abdominal problems that were scored >4 were classified as serious.
Mean run times (for the two different treatments, as well as for the first and second runs) were compared using a paired t test. Other possible factors that could have influenced GI tolerance (e.g., training status, fluid intake, body-weight loss) were analyzed using Spearman's correlation coefficient. For those tests, p values <.05 were considered significant.
All statistics were performed using SPSS 15 for Windows (SPSS Inc., Chicago, IL).
Results
Environmental Race Conditions
All runs took place in relatively mild conditions that were comparable in each study. Average weather conditions across the three experimental days in Study 1 were temperature 7 ± 2 °C, barometric pressure 1,013 ± 25 hr Pa, wind speed 5 ± 3 km/hr, and relative humidity 90% ± 1%. Study 2 took place in slightly warmer conditions: temperature 12 ± 2 °C, barometric pressure 1,018 ± 9 hr Pa, wind speed 7 ± 4 km/hr, and relative humidity 68% ± 7%.
CHO Intake and Fluid Balance
Study 1. The average CHO intake of the participants during the runs was 1.0 ± 0.1 g/min in the MOD trial and 1.4 ± 0.2 g/min in the HIGH trial. Water intake was similar between trials, with 259 ± 133 ml (min 28 ml, max 552 ml) during the MOD trial and 245 ± 141 ml (min 82 ml, max 523 ml) during the HIGH trial. Mean body-mass loss was 0.9 ± 0.2 kg (min 0.5 kg, max 1.7 kg) during the MOD trial and 1.0 ± 0.2 kg (min 0.4 kg, max 1.5kg) during the HIGH trial.
Study 2. The average CHO intake in the GLU trial was 1.4 ± 0.1 g/min and was 1.4 ± 0.1 g/min in the GLC+FRC trial. Water intake was 370 ± 166 ml (min 131 ml, max 842 ml) in the GLU trial and 409 ± 153 ml (min 157 ml, max 785 ml) in the GLU+FRC trial. Mean body-mass loss was 1.0 ± 0.3 kg (min -0.3 kg, max 1.3 kg) in the GLU trial and 1.1 ± 0.4 kg (min -0.2 kg, max 1.6 kg) in the GLU+FRC trial.
GI Symptoms During the Runs
For both studies, posttrial questionnaires were evaluated for all runners. Specifically, the runners who experienced severe GI symptoms showed that they had kept to the same routine before each trial, and none had an excessively high fiber or fat intake. Study 1. During both trials the questions on GI symptoms were mostly scored at the low end of the scale (no problem at all, very minor problems). Scores ranged from 0 to 9 with both treatments. Mean values, as well as minimum and maximum scores, are presented in Table 2 . Mean scores ranged from 0.00 ± 0.00 (diarrhea) to 0.97 ± 1.55 (upper abdominal cramps) with the MOD dose and from 0.09 ± 0.51 (loose stool and diarrhea) to 1.12 ± 1.90 (upper abdominal cramps) with the HIGH dose.
The differences in scores between treatments are displayed in Table 3 . Our primary outcome showed that mean scores for upper abdominal, lower abdominal, and systemic problems were not significantly different. Secondary measures showed higher scores for nausea with the HIGH dose (effect estimate = .47, SE = .19, p = .02).
Three (9%) of the runners reported serious symptoms (score >4) with the HIGH but not with the MOD dose, and 1 runner (3%) reported serious symptoms with both doses.
There was no difference between the occurrence of GI symptoms in male and female runners. Participants' history of GI symptoms, which was reported in the prerace questionnaire, was positively correlated with the occurrence of GI symptoms during the runs (Figure 1 ; upper abdominal problems, r = .70, p < .001. Figure 2 ; lower abdominal problems, r = .46, p = .001).
No correlations were found between indicators of training experience (frequency of running per week, mean run times) and GI symptoms. Furthermore, fluid intake and body-mass loss during Study 1 did not correlate with GI symptoms.
Study 2. One runner had to stop during one trial (GLU+FRC) because of GI symptoms and is included in the GI results. Mean values, as well as minimum and maximum scores, are presented in Table 4 . Most runners reported scores at the low end of the scale. Scores ranged from 0 to 9 with both treatments. Mean scores ranged from 0.00 ± 0.00 (diarrhea and loose stool) to 1.23 ± 1.78 (upper abdominal cramps) with GLU and from 0.13 ± 0.73 (diarrhea) to 1.27 ± 1.78 (upper abdominal cramps) with GLU+FRC.
The differences in scores between treatments are displayed in Table 5 . Our primary outcome showed that mean scores for upper abdominal, lower abdominal, and systemic problems were not significantly different. Secondary measures showed an increased score for symptoms with the GLU+FRC gel for reflux (effect estimate = -.46, SE = .23, p = .024), intestinal cramps (effect estimate = -.42, SE = .2, p = .041), and loose stool (effect estimate = -.38, SE = .2, p = .043).
Nine (19%) of the runners reported serious symptoms only with the GLU+FRC gel, 5 (10%) runners reported serious symptoms only with the GLU gel, and 2 (4%) runners reported serious symptoms with both treatments.
Reported GI symptoms during the runs were strongly correlated with history of GI symptoms as assessed in the prerace questionnaire (Figure 3 ; upper abdominal problems, r = .89, p < .001. Figure 4 ; lower abdominal problems, r = .90, p < .001).
There was no difference between the occurrence of GI symptoms in male and female runners. No correlations have been found between frequency of running per week and GI symptoms or between mean run times and GI symptoms. Fluid intake and body-mass loss during Study 2 did not correlate with GI symptoms.
Performance
Study 1. Mean run times did not differ significantly between the MOD (1:12:53 ± 0:7:24 hr:min:s) and HIGH (1:13:06 ± 7:45 hr:min:s) trials. Sixteen runners were faster with the MOD dose, and 18 were faster with the HIGH dose. Mean run times between the first run of each participant (1:13:01 ± 0:7:09 hr:min:s) and the second run (1:12:58 ± 7:07 hr:min:s) did not differ significantly.
Study 2. Results of running times are expressed for 47 runners; 1 runner did not finish one trial. Mean run times between the GLU trial (1:14:25 ± 0:7:17 hr:min:s) and the GLU+FRC trial (1:14:41 ± 0:7:10 hr:min:s) did not differ significantly. Twenty-four participants ran faster with the GLU gel and 25 ran faster with the GLC+FRC gel. The mean run time for the second run (1:14:04 ± 0:7:01 hr:min:s) was significantly (p = .005) faster than for the first run (1:15:02 ± 0:7:24 hr:min:s). Thirty participants ran faster during the second run, and 17 had a faster first run. 
Discussion
The aim of the current studies was to test whether high CHO intake rates and varying CHO blends in the form of gels had an impact on GI tolerance. High-intensity exercise, in particular running, has been linked to a high prevalence of GI distress (Peters et al., 1999) . Consequently, a high prevalence of GI symptoms could have been expected. Furthermore, a bias toward a higher score of symptoms could have been anticipated because no placebo trial was included. Nevertheless, mean GIsymptom scores were on the low end of the scale during all trials and there were no treatment differences, indicating that both gels were well tolerated by the vast majority of the runners.
Effect of CHO Intake Rate on GI Tolerance
The first study examined different rates of CHO ingestion (MOD = 1.0 ± 0.1 g/ min; HIGH = 1.4 ± 0.2 g/min) and showed an equally good tolerance for both treatments. The only symptom that occurred more often with the HIGH dose was nausea, suggesting that a high intake of CHO might lead to more nausea. However, because the test results were not corrected for multiplicity the observation must be treated with caution. Generally good GI tolerance with scores below 4 was reported among 30 of the runners (88%). Nevertheless, 3 runners (9%) had serious symptoms (score >4) only with the HIGH intake, and 1 runner (3%) had serious GI symptoms with both MOD and HIGH intake, indicating individual GI variability in tolerating CHO intake. Because a high intake rate of gel with a similar composition as in Study 1 was used in the GLU+FRC trial in Study 2, this trial is directly comparable to the HIGH trial in Study 1. It is surprising that more runners (23%) showed serious GI symptoms during the GLU+FRC trial in Study 2 than the HIGH trial in Study 1 (12%). This difference could be mainly the result of a different disposition to GI symptoms based on GI history of the different runners in each study. In both studies the history of GI symptoms as assessed in the prerace questionnaire was highly correlated with GI symptoms during the race. Another reason for generally higher scores in the second study could be the different environmental conditions involving considerably warmer weather. It is well established that decreased blood flow in the gut can lead to GI symptoms (Brouns & Beckers, 1993; Gil, Yazaki, & Evans, 1998) . This could have been caused by increased blood shunting to the skin under warmer conditions and also by higher fluid losses during the second study.
Whether the prevalence of GI symptoms in our studies is in accordance with previous studies that investigated CHO intake during running is difficult to judge, because different methodologies and statistical approaches were used. Van Nieuwenhoven et al. (2005) investigated the effect of a CHO sports drink and water on GI tolerance during an 18-km run. A similar 10-point scale (1-10) was used, and generally higher mean scores (2.0-5.5) were reported, not only in the CHO trial but also in the water trial. In the study of Burke et al. (2005) CHO gel was given at an intake rate of about 1 g/min, and a 15% incidence of GI symptoms was reported. This intake rate matches the CHO administration in our MOD trial in Study 1, in which 3% of the runners reported serious GI symptoms >4. The slightly lower scores in our study could again be a result of different predisposition to GI problems of the runners, as well as cooler environmental conditions.
Whether all occurring GI symptoms are related to CHO intake is not possible to answer from this set of studies because no placebo trials were implemented into the study designs to keep statistical power high. Previous studies have shown a high prevalence of GI symptoms during endurance events, running in particular. Prevalence was reported as 10-87%, depending on the sport, duration, and method of investigation (Keeffe, Lowe, Goss, & Wayne, 1984; Riddoch & Trinick, 1988; Sullivan, 1981) . These findings are confirmed by the high incidence of GI problems reported in the water trial in the study by van Nieuwenhoven et al. (2005) . It therefore must be assumed that not all GI symptoms reported in our study were caused by CHO intake.
Effect of Different CHO Composition on GI Tolerance
One of our hypotheses was that because of the use of different intestinal transporters for glucose and fructose, and therefore a possibly higher absorption of a combination of GLU+FRC than GLU, less residual CHO would be present in the intestine with the GLU+FRC mix. Residual CHO in the lower intestine can lead to GI distress, most likely as result of water retention in the gut because of a higher osmotic load (Corazza et al., 1988; Ravich et al., 1983; Rumessen & Gudmand-Hoyer, 1986 ). In addition, fermentation by bacteria in the gut can lead to gas production, as well as to production of fatty acids, which might lead to higher motility of the gut (Cherbut, Aube, Blottiere, & Galmiche, 1997) .
We did not observe a difference in tolerance between the GLU+FRC and GLU gels in this study. One reason that a better tolerance of GLU+FRC was not shown could be that GI tolerance is not exclusively influenced by absorption and residual CHO in the intestine. As discussed previously, factors such as reduced blood flow to the gut or mechanical stress from running can lead to GI symptoms. These mechanisms were not expected to be different between treatments. In addition, a superior effect of faster absorption of different CHOs would be expected later in exercise. Previous studies showed that enhanced exogenous CHO oxidation from a GLU+FRC blend compared with GLU starts to occur after approximately 45 min of exercise Wallis et al., 2005) . With an average duration of ~70 min for the run, it is possible that residual CHO in the GI tract during the two CHO trials was not significantly different. Even in a prolonged exercise intervention, in which significant differences in residual CHO might result between different CHO treatments, we would hypothesize that osmotic effects and fermentation would contribute to adverse GI symptoms in the GLU-only treatment.
Although in Study 2 overall there was no difference between the two different CHO gels, 9 (19%) runners had serious symptoms only with the GLU+FRC gel and 5 (10%) had serious symptoms only with the GLU gel, suggesting that tolerance is highly individual, which is supported by the significant correlations between GI symptoms and history of symptoms. Reflux, intestinal cramps, and loose stools occurred more often with the GLU+FRC gel, but, as stated earlier, this does not necessarily mean that the intake of GLU+FRC gel leads to more of these symptoms because the test results were not corrected for multiplicity, so further confirmation is needed.
Differences in Performance With Varying CHO Gel Intake
As an indicator of differences in performance between treatments, running times were compared. Mean running times were not different between the MOD and the HIGH treatment in the first study. This may seem in contrast with previous reports of improved performance with CHO feeding during prolonged exercise. However, when the exercise duration is less than ~70 min, CHO availability may not be the main limiting factor on performance. It has been suggested that the mechanisms for fatigue during this type of exercise are not metabolic (Carter, Jeukendrup, Mann, & Jones, 2004 ) but rather are mediated by central mechanisms. If this is the case, no performance benefits from a high CHO intake compared with a moderate intake would be expected in this short time period. It is equally important to note that no negative effect of the HIGH intake because of GI symptoms was observed, which could have a large performance impact in longer duration exercise situations when endogenous CHO is limiting. Likewise in Study 2, there was no difference between treatments, but it must be noted that 1 runner had to stop because of GI symptoms during the GLU+FRC trial. In addition, a significant difference has been shown between run times for the first and the second runs of each participant, possibly indicating a substantial "learning effect." This effect is likely a result of the chosen group's being well-trained but not necessarily competitive runners; a rather high within-athlete variation is to be expected, and learning effects may be more common (Hopkins & Hewson, 2001 ).
Individual Predisposition to GI Problems
A consistent finding in both our studies that seems worthy of note was the strong correlation between a history of GI distress and the reported GI symptoms during the trials. This suggests that there is an individual predisposition to GI problems during exercise, and, although there has been anecdotal evidence presented to support this idea, as far as we are aware this has not been clearly documented before. For athletes, as well as for sports nutritionists, this appears to be very important because it shows that in terms of tolerance, personal advice and individual testing of food and drink intake during exercise are vital.
In summary, the current study showed that high doses of CHO (1.4 g/min) in gel form were well tolerated by most runners. Nevertheless, 3-23% of the runners experienced GI symptoms during the runs, and the severity of these symptoms correlated with their history of GI complaints. In addition, although we did not find an overall different tolerance between the GLU and GLU+FRC treatments, some individuals showed more symptoms with one or the other gel. It should therefore be advised that individual athletes, especially those who experience GI problems frequently, test their tolerance during hard training sessions, ideally under conditions similar to those of the races they aim to compete in.
